Editorials

Treatment of multiple myeloma

BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7415.575 (Published 11 September 2003) Cite this as: BMJ 2003;327:575
  1. Seema Singhal, director (s-singhal@northwestern.edu)
  1. Multiple Myeloma Program, Division of Hematology and Oncology, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA

    New drugs raise hope for the future

    Multiple myeloma is a malignant disease of plasma cells that is characterised by secretion of paraprotein, humoral immunodeficiency, anaemia, lytic bone lesions, and kidney dysfunction. Although the median survival of patients with multiple myeloma has improved from seven months to five years with treatment, the disease remains largely incurable.1

    Conventional treatment includes melphalan and prednisone, now used sparingly because of its propensity to compromise collection of haematopoietic stem cells, other combinations, and regimens containing high dose corticosteroids. The latter—including dexamethasone; vincristine, doxorubicin, and dexamethasone; and cyclophosphamide, vincristine, doxorubicin, and methylprednisolone—are preferred for induction because of their excellent anti-myeloma activity and lack of marrow toxicity.

    High dose chemotherapy, particularly melphalan, with autologous haematopoietic stem cell transplantation improves response rates and their duration and survival compared with conventional chemotherapy. It is now commonly used as consolidation treatment.1 The superiority of consolidation with haematopoietic stem cell transplantation over continued conventional treatment has been confirmed in two randomised studies with a 12 month increase in median overall survival.2 3 Another study has shown …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe